文献速递炎症性肠病

儿童溃疡性结肠炎疾病结局预测模型的验证:一项多中心前瞻性起始队列研究

Validation of predictive models for disease outcomes in paediatric ulcerative colitis: A multicentre prospective inception cohort.
PubMed 文献 · Aliment Pharmacol Ther · 2023-05-29

该研究在17个中心前瞻性纳入223例新诊断儿童溃疡性结肠炎(UC)患者,验证PROTECT、Schechter和PIBD-ahead等预测模型。PROTECT模型对3个月无激素缓解(SFR)预测良好(AUC 0.78),但对12个月预测不佳(AUC 0.57);Schechter标准预测12个月持续SFR的灵敏度/特异度/PPV/NPV为50%/60%/35%/74%。其他模型准确性不足,强调模型临床应用前需外部验证。

要点

  • PROTECT模型对3个月SFR预测良好(AUC 0.78),对12个月预测不佳(AUC 0.57)。
  • Schechter标准预测12个月持续SFR的灵敏度/特异度/PPV/NPV为50%/60%/35%/74%。
  • 仅诊断时和3个月时的PUCAI评分可预测急性重症结肠炎(ASC)。

核心结论

  • PROTECT模型对3个月SFR具有良好预测效用,但对12个月SFR预测不佳。
  • 其他预测模型未达到足够准确性,远低于原始研究报告的准确性。
  • 这强调任何预测模型在临床实施前需进行外部验证。

研究设计与样本

  • 多中心前瞻性起始队列研究,纳入17个中心新诊断的223例儿童UC患者。
  • 在疾病起始、3个月、12个月及末次访视时随访。
  • 结局包括无激素缓解(SFR)和急性重症结肠炎(ASC)。

主要发现

  • 223例患儿中,轻度、中度和重度疾病分别为74例(34%)、97例(43%)和52例(23%)。
  • 3个月SFR率为35%,12个月为47%(诊断时轻度病患者62% vs 中重度病患者41%;p=0.01)。
  • 36例(16%)患儿在诊断后第一个月内发生ASC,53例(24%)在第一年内发生。
  • PROTECT模型预测3个月和12个月SFR的AUC分别为0.78 [95% CI 0.65-0.92] 和0.57 [95% CI 0.47-0.66]。
  • Schechter标准预测12个月持续SFR的灵敏度/特异度/PPV/NPV为50%/60%/35%/74%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Several studies have proposed models to predict disease outcomes in paediatric ulcerative colitis (UC), notably PROTECT, Schechter and PIBD-ahead, but none has been validated by external cohorts AIM: To explore these models in a prospective multicentre inception cohort METHODS: Children newly diagnosed with UC in 17 centres were followed at disease onset and 3 and 12 months thereafter, as well as at last visit. Outcomes included steroid-free remission (SFR) and acute severe colitis (ASC). RESULTS: Of the 223 included children, 74 (34%), 97 (43%) and 52 (23%) presented with mild, moderate and severe disease, respectively. SFR rate was 35% at 3 months and 47% at 12 months (62% of those with mild disease at diagnosis vs. 41% in moderate-severe disease; p = 0.01). Thirty-six (16%) children developed ASC during the first month after diagnosis, and 53 (24%) during the first year. The AUC of the PROTECT model for predicting SFR at 3 and 12 months was 0.78 [95% CI 0.65-0.92] and 0.57 [95% CI 0.47-0.66], respectively. The sensitivity/specificity/PPV/NPV of Schechter's criteria to predict sustained SFR at 12 months was 50%/60%/35%/74%. ASC was predicted only by the PUCAI score at diagnosis and at 3 months. CONCLUSIONS: The PROTECT model had a good predictive utility for SFR at 3 months, but not at 12 months. The other predictive models did not achieve sufficient accuracy, which was far from that reported in the original studies. This highlights the necessity for external validation of any prediction model prior to its implementation into clinical practice.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Atia O, Klomberg RCW, de Ridder L, et al. Validation of predictive models for disease outcomes in paediatric ulcerative colitis: A multicentre prospective inception cohort. Aliment Pharmacol Ther. 2023. PMID: 37248642. doi:10.1111/apt.17544

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。